It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Users of weight loss drugs such as Wegovy and Mounjaro, along with those who use type 2 diabetes drug Ozempic for weight loss ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...

You might have seen people talking about a 'golden dose' on social media in regards to weight loss jabs, but what exactly is ...

Called orforglipron, it’s part of a growing class of drugs known as GLP-1s, which include Novo Nordisk’s Ozempic and Wegovy. The drugs mimic a naturally occurring hormone in the body that helps ...

Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

Wall Street stocks rebounded Wednesday led by Apple and other large tech companies as markets largely shrugged off US ...